Norway· NO-ID_D5B19F6F-6EEA-4412-B8BA-229414703A1F
Aimovig
A erenumab product containing erenumab, registered in Norway by Novartis Europharm Limited (1). The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Erenumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Erenumab · ATC N02CD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Erenumab
- Manufacturer
- Novartis Europharm Limited (1)
- Country
- Norway (NO)
- ATC code
- N02CD01
- ATC class
- Erenumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_D5B19F6F-6EEA-4412-B8BA-229414703A1F
- no_varenummer4218703 x 1NOK 9969.1
- no_varenummer1893121NOK 3347.2
- gtin7613421185343
- gtin7613421042356
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Erenumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAimovig
- PolandAimovigNovartis Europharm Limited
- United StatesAIMOVIGAmgen Inc
- FinlandAimovigParanova Oy
- CzechiaAIMOVIGNovartis Europharm Limited, Dublin
- BelgiumAimovig 140 mgNovartis Europharm
- IcelandAimovigNovartis Europharm Limited*
- NetherlandsAimovig 140 mg oplossing voor injectie in voorgevulde penNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Aimovig
- Liechtenstein · Aimovig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eeae7974-e424-4543-8643-588e09aef2cf GET /v1/drugs/eeae7974-e424-4543-8643-588e09aef2cf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Erenumab",
"merkevare_id": "ID_D5B19F6F-6EEA-4412-B8BA-229414703A1F",
"name_form_strength": "Aimovig inj, oppl 140 mg/ml",
"prescription_group": "C"
}See everything about erenumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.